EyeGate completes enrollment in ocular surface inflammation study
EyeGate Pharmaceuticals has completed enrollment in a phase 2 proof-of-concept study investigating PP-001 in patients with ocular surface inflammation, according to a press release.
Twenty-one patients in Austria were enrolled in the randomized, double-masked, placebo-controlled study, which is designed to investigate the safety, tolerability and efficacy of PP-001 in patients with ocular surface inflammation due to dry eye disease. Patients are being treated with PP-001 0.15% or placebo for 12 days.
“We believe our proof-of-concept study will further validate the clinical utility of PP-001, which has the potential to overcome off-target side effects and safety issues associated with [dihydroorotate dehydrogenase] inhibitors with greater specificity and best-in-class picomolar potency,” Brian Strem, PhD, president and CEO of EyeGate, said in the release.
Topline data are expected in the fourth quarter, along with an investigational new drug filing in the United States.